

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/687,122
Filing Date	October 13, 2000
First Named Inventor	Alessandra BOE et al.
Group Art Unit	1646
Examiner Name	J. Murphy
Attorney Docket Number	BOE-1A

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent Number	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
b	AA	WO	92/13095			08-06-1992		
b	AB	EP	92/512528			11-11-1992		
b	AC	WO	94/06476			03-31-1994		
b	AD	WO	95/03827			02-09-1995		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
b	AE	<i>The Merck Manual of Diagnosis and Therapy</i> , Sixteenth Edition, Robert BERKOW, M.D., Editor-in-Chief, 1992, Merck & Co., Inc., New Jersey, pp. 71, 2664 and 2780	
b	AF	H.D. DANENBERG, et al., "Dehydroepiandrosterone Protects Mice from Endotoxin Toxicity and Reduces Tumor Necrosis Factor Production", <i>Antimicrob Agents Chemother</i> , vol. 36, no. 10, 1992, pp. 2275-2279	RECEIVED APR 05 2002
b	AG	R.F. VAN VOLLENHOVEN et al., "In Patients With Systematic Lupus Erythematosus, treatment with Oral Dehydroepiandrosterone Restores Abnormally Low In Vito Production of IL-2, IL-6 and TNF-alpha", <i>Arthritis and Rheumatism</i> , vol. 37, no. 9, suppl., 1994, p. 407	
b	AH	J.Y. YANG et al., "Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and its Metabolite DHEA", <i>TECH CENTER 1600/2900</i> vol. 9, no. 8, 1993, pp. 747-754	
b	AI	M. CUTOLO et al., "Immunomodulatory Mechanisms Mediated by Sex Hormones in Rheumatoid Arthritis", <i>Annals of the New York Academy of Sciences, Basis for Cancer Management. Conference on Propedeutics to Cancer Management</i> , France, Italy, April 1-6, 1995, vol. 784, 1996, pp. 237-251	
b	AJ	F.C. KULL, "Reduction in Tumor Necrosis Factor Receptor Affinity and Cytotoxicity by Glucocorticoids", <i>Biochem., Biophys. Res. Commun.</i> , vol. 153, no. 1, 1988, pp. 402-409	
b	AK	W.P. AREND et al., "Inhibition of the Production and Effects of Interleukin-1 and Tumor Necrosis Factor Alpha in Rheumatoid Arthritis", <i>Arthritis Rheum.</i> , vol. 38, no. 2, February 1995, pp. 151-160	
b	AL	E. GIRARDIN et al., "Cytokines et antagonists dans le choc septique", <i>Schweiz. Med. Wschr.</i> , vol. 123, no. 11, 1993, pp. 480-491	
b	AM	S.M. OPAL et al., "Tumor Necrosis Factor Receptor-Fc Fusion Protein (sTNFR:Fc) in the Treatment of Experimental Pseudomonas Spesis", <i>Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , vol. 33, no. 0, 1993, p. 378	
b	AN	E. TARTOUR et al., "Anti-Cytokines: Promising Tools for Diagnosis and Immunotherapy", <i>Biomed Pharmacother</i> , vol. 48, no. 10, 1994, pp. 417-424	
b	AO	D. RUSSEL et al., "Synergistic Protection Against Lethal Endotoxemia by Treatment with Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein", <i>Lymphokine and Cytokine Research</i> , vol. 12, no. 5, 1993, p. 377	
b	AP	<i>Stedman's Medical Dictionary</i> , 26 Ed. Williams & Wilkins, Baltimore, pp. 1608-1609, 1995	

Examiner Signature

Date Considered

6-10-02

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.